Latest Regulatory Engagement News

NobleOak Life has obtained in-principle ex gratia relief from Victorian insurance duty on premiums paid in early 2025, potentially reducing its previously provisioned $6.5 million liability.

Ausgold Limited is accelerating development at its Katanning Gold Project, with siteworks underway, modular accommodation nearing completion, and key engineering and power contracts signed to support a final investment decision by end-2026 and first gold production in mid-2028.

Taiko Critical Minerals secures a conditional NZ$20 million government funding offer to co-finance a NZ$40 million wet separation plant at Barrytown, boosting project credibility and accelerating development plans.

PEXA faces a proposed 20% cut in regulated ELNO service fees, risking a $70 million revenue reduction over a year. The company urges a phased approach to mitigate business impact as IPART opens public consultation.

Prodigy Gold is progressing key regulatory approvals to restart mining at its Old Pirate gold mine, supported by encouraging ore sorting testwork that significantly upgrades gold grades and promises operational efficiencies.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.

Mount Hope Mining has engaged R.W. Corkery & Co to lead environmental baseline studies and prepare for an Environmental Impact Statement at its Mt Solitary gold project, a crucial step towards mining approvals in NSW.

Island Pharmaceuticals has presented encouraging Phase 2a results for its dengue antiviral ISLA-101, demonstrating safety, effective blood concentrations, and meaningful viral load reductions at the Asia Dengue Summit.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

The Therapeutic Goods Administration has broadened the range of clinicians eligible to participate in psychedelic-assisted psychotherapy, a move set to speed up recruitment and improve patient access across Emyria’s national Empax network.